Heart Of China For Mac

The trials were launched on Sept. 13 by clinicians at the TEDA International Cardiovascular Hospital in north China's Tianjin Municipality. After being implanted into a 63-year-old male patient to replace his failed heart, the device has functioned as a pump to deliver blood to the whole body, significantly alleviating the symptoms of heart failure, said Liu Xiaocheng, lead researcher of the clinic program and head of the hospital.

Called HeartCon, the artificial heart weighs only 180 grams and is smaller than the size of a fist. It is an outcome of long-term cooperation between the hospital and the China Academy of Launch Vehicle Technology, the country's leading rocket maker.

Download File 🔥 https://byltly.com/2xZnE5 🔥

Scientists began developing the artificial heart in 2009. They used magnetic and fluid levitation, which are used in rocket servo technology, to produce an implantable third-generation ventricular assistive device, a mechanical pump to support heart functions while causing less damage to patients' blood than previous types.

Since the artificial heart uses a blood pump and needs electrical energy to generate power, it works on external batteries. Implanting an artificial heart requires a wire, thinner than a chopstick, to pass through the patient's belly to connect the controller and external batteries.

Animal experiments started in 2013. A sheep with the artificial heart survived 120 days. Four years later, scientists implanted the HeartCons into six sheep and set a new record as one of them survived 180 days.

There are at least 16 million people with failing hearts in China. For patients who are in advanced stages of heart failure, transplants are the only solution. However, transplants are limited by a lack of donors and many die while waiting.

"Since 2013, the implanted ventricular assistive devices worldwide have surpassed heart transplants in number and survival rate," said Liu. "The longest survival time of patients with an artificial heart is more than 15 years."

Furthermore, patients with an artificial heart only need anticoagulants after surgery. They don't require various anti-rejection drugs that heart transplant recipients have to take, said Liu, adding that with advancing technology, the artificial heart can completely replace transplants.

Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death, hospitalisation for heart failure (HF), or urgent HF visits in adults with symptomatic chronic HF. Forxiga has previously been approved in China for HF patients with reduced ejection fraction (HFrEF) meaning that Forxiga is now approved in China to reduce the risk of cardiovascular death and hospitalisations in adult patients with symptomatic chronic HF regardless of ejection fraction phenotype.

HF is a complex syndrome that occurs when the heart cannot pump enough blood around the body.3 HF affects approximately 4.5 million people in China.4 Around half of HF patients die within five years of diagnosis.5 Patients with ejection fraction above 40% are at greater risk of death and hospitalisation and experience an especially high burden of symptoms and physical limitations, and consequently have a poor quality of life.6 The economic burden of HF in China is huge in terms of healthcare costs and resource utilisation, and hospitalisation is the major contributor to the HF treatment burden - the mean hospital stay for HF patients is 30 days in one year.7

Heart Failure

Heart Failure (HF) is a chronic, long-term condition that worsens over time.8 It affects nearly 64 million people globally9 and is associated with substantial morbidity and mortality.10 Chronic HF is the leading cause of hospitalisation for those over the age of 65 and represents a significant clinical and economic burden.11 There are several types of HF often defined by left ventricular ejection fraction (LVEF), a measurement of the percentage of blood leaving the heart each time it contracts, including HFrEF (LVEF less than or equal to 40%), HFmrEF (LVEF 41-49%) and HFpEF (LVEF greater than or equal to 50%).12 Approximately half of all HF patients have HFmrEF or HFpEF, with few therapeutic options available.13

1. Jhund PS, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med. 2022;28(9):1956-64.

13. Kosiborod MN, et al. The effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and mildly reduced or preserved ejection fraction: results from the DELIVER Trial. Presented at: American Heart Association (AHA) Scientific Sessions 2022, 5-7 November 2022, Chicago, Illinois, USA.

In a pilot experiment, the researchers collected heart tissue samples from 15 people during cardiac surgeries, as well as pre- and post-operation blood specimens from half of the participants. Then the team analyzed the samples with laser direct infrared imaging and identified 20 to 500 micrometer-wide particles made from eight types of plastic, including polyethylene terephthalate, polyvinyl chloride and poly(methyl methacrylate). This technique detected tens to thousands of individual microplastic pieces in most tissue samples, though the amounts and materials varied between participants. All of the blood samples also contained plastic particles, but after surgery their average size decreased, and the particles came from more diverse types of plastics.

Chinese scientists have also developed superaligned carbon nanotube heart patches to guide oriented cardiomyocyte growth and promote electrophysiological homogeneity for engineered cardiac tissues [16]. The superaligned carbon nanotube-based, one-piece pacemaker electrode may also be potentially applied for cardiac resynchronization therapy in myocardial infarction patients with HF [16]. We hope that these Chinese-developed medical materials and devices will soon be approved for clinical trials and may one day provide new hope for HF patients.

The epidemiology of valvular heart disease (VHD) has changed markedly over the last 50 years worldwide, and the prevalence and features of VHD in China are unknown. The objective of this study was to investigate the current status and etiology of VHD in China.

In China, rheumatic heart disease was still the major cause of the VHD, with a significant increase in degenerative heart disease. Age and hypertension are important and easily identifiable markers of VHD.

A standardized questionnaire was specifically developed for this study to collect demographic characteristics, lifestyle and history of disease by experienced medical staff. The history of cardiac diseases, such as myocardial infarction, coronary artery bypass grafting surgery, percutaneous coronary intervention, congestive heart failure and so on, was documented in detail. For the purpose of identifying comorbidities, all instances of hypertension, stroke, hyperlipidemia, diabetes mellitus, and chronic kidney disease (CKD) were also recorded in the questionnaire. Subsequently, physical examination, electrocardiogram, and echocardiography were performed on each participant at the local medical centers (town/county hospitals). Blood samples were collected to test for blood lipids, glucose, and creatinine in a designated lab.

VHD is a progressive disease that may be silent for decades. It has been reported that early identification and treatment could avoid and delay heart failure from long-term overvolume and overpressure. Auscultation is a widely available method to detect VHD in large populations, but its sensitivity is limited [35]. Therefore, echo screening for early identification and prevention, as recommended by the WHO [36] in the 1980s, might also be helpful given the aging tendency.

Ischemic heart disease (IHD) is a type of heart attack caused by myocardial ischemia as a result of narrowing or blockage of blood vessels that supply the heart [1, 2]. IHD is the most fatal disease [3, 4] and the leading cause of health loss from cardiovascular disease (CVD) worldwide [5], especially in low- and middle-income countries [6]. Although the mortality rate of IHD has decreased in high-income countries, it remains the leading cause of death [1, 7].

The BRI strategy is at heart an initiative to better penetrate European markets (essentially the European Union), which are the primary destination for Chinese products, ahead of Southeast Asian countries and the United States. Africa therefore has very little part to play in the BRI, and the investment China has made under this moniker are heavily concentrated in Egypt and the Horn of Africa, along the route to the Suez Canal.

Endpoints at 30 days included major adverse cardiovascular and cerebrovascular events (MACCEs) such as cardiovascular death, myocardial re-infarction, cerebral stroke, cardiogenic shock, and heart failure.

Paeoniflorin, from the white peony root extract, is a primary active constituent in traditional Chinese medicines. It has been used to treat cardiovascular conditions such as heart attack and atherosclerosis.

After all, he was their dear friend, the man who introduced open-heart surgery to China in 1980, when as a visiting professor who could speak some Mandarin he spent a month living in an apartment that had hot water between 5 and 8 p.m. By day, he trained doctors at a medical school where a man delivered ice through the hospital loaded on a bicycle with muddy wheels.

The department chair is a man who was an intern for some of the operations President Nelson performed during his training visit in 1980. He thanked President Nelson for inspiring him to specialize in heart surgery. be457b7860